Navidea Biopharmaceuticals Stock Beta
| NAVBDelisted Stock | USD 0.1 0.01 9.45% |
Navidea Biopharmaceuticals fundamentals help investors to digest information that contributes to Navidea Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Navidea Pink Sheet. The fundamental analysis module provides a way to measure Navidea Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Navidea Biopharmaceutica pink sheet.
Navidea |
Navidea Biopharmaceuticals Company Beta Analysis
Navidea Biopharmaceutica's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Navidea Biopharmaceutica Beta | 1.5 |
Most of Navidea Biopharmaceutica's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Navidea Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Navidea Biopharmaceuticals has a Beta of 1.5029. This is 74.76% higher than that of the Biotechnology sector and 8.12% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Navidea Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Navidea Biopharmaceutica's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Navidea Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Navidea Biopharmaceutica by comparing valuation metrics of similar companies.Navidea Biopharmaceutica is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Navidea Biopharmaceutica will likely underperform.
Navidea Fundamentals
| Return On Equity | -11.0 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 3.5 M | ||||
| Shares Outstanding | 100.08 M | ||||
| Shares Owned By Insiders | 35.43 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 2.69 M | ||||
| Price To Earning | 0.53 X | ||||
| Price To Book | 8.16 X | ||||
| Price To Sales | 84.14 X | ||||
| Revenue | 65.65 K | ||||
| Gross Profit | (119.3 K) | ||||
| EBITDA | (14.05 M) | ||||
| Net Income | (15.18 M) | ||||
| Cash And Equivalents | 328.01 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.43 M | ||||
| Debt To Equity | 1.20 % | ||||
| Current Ratio | 0.22 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (8.99 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 8.04 M | ||||
| Total Asset | 4.37 M | ||||
| Retained Earnings | (388 M) | ||||
| Working Capital | (6.74 M) | ||||
| Current Asset | 12.58 M | ||||
| Current Liabilities | 6.18 M | ||||
| Net Asset | 4.37 M |
About Navidea Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Navidea Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Navidea Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Navidea Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |